# US 2019/0375710 A1 · Compounds and methods for inhibiting emt pathways to treat cancer, organ fibrosis and metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375710 A1
- Document ID: US20190375710A1
- Status: Published application
- Kind: A1
- Application number: 16/487,770
- Filed: 2018-02-19
- Published: 2019-12-12
- Earliest claimed: 2017-02-22
- Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education; Universite Le Havre Normandie
- Applicants: University of Pittsburgh-Of the Commonwealth System of Higher Education; Universite Le Havre Normandie
- Inventors: Abdelhadi Rebbaa; Sebastien Comesse; Adam Daich; Martin Lawson; Catalin Pintiala
- Web page: https://patentgrep.com/patent/US20190375710A1

## CPC

- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- C07D 213/02: having three double bonds between ring members or between ring members and non-ring members
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/80: in position 3
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I:
wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl;
R1 is hydrogen, alkoxy, or substituted alkoxy;
R2 is hydrogen, alkyl, or substituted alkyl; and
R3 is hydrogen, alkyl, or substituted alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is a C1-C6 alkyl; or —(CH2)a—Ar, wherein a is 1 to 6 and Ar is an aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Ar is phenyl or substituted phenyl.

### Claim 4 (depends on 3)

The compound of claim 3, wherein Ar is phenyl substituted with at least one halogen, alkoxy, and/or alkyl.

### Claim 5 (depends on 2)

The compound of claim 2, wherein Ar is an O-heteroaryl, an S-heteroaryl, or a N-heteroaryl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R is benzyl or substituted benzyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R is benzyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R1 is hydrogen.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 is —O—Ar, wherein Ar is an aryl, substituted aryl, heteroaryl or substituted heteroaryl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein Ar is phenyl or substituted phenyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is hydrogen.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R2 is C1-C6 alkyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R3 is C1-C6 alkyl.

### Claim 14 (depends on 1)

The compound of claim 1, wherein R3 is ethyl.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable excipient.

### Claim 16 (depends on 1)

A method for treating an epithelial-mesenchymal transition-associated disorder or an adenosine monophosphate-activated protein kinase-associated disorder in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 17 (depends on 16)

The method of claim 16, wherein the epithelial-mesenchymal transition-associated disorder is cancer.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cancer is selected from skin cancer, breast cancer, colon cancer, lung cancer, or blood cancer.

### Claim 19 (depends on 16)

The method of claim 16, wherein the epithelial-mesenchymal transition-associated disorder is a fibrotic disorder.

### Claim 20 (depends on 19)

The method of claim 19, wherein the fibrotic disorder is selected from those that affect the liver, lung, kidney, heart, and the skin, amyotrophic lateral sclerosis, multiple sclerosis, tuberous sclerosis, thrombosis, neurofibromatosis, neuro-inflammation, inflammatory pain, and neuropathic pain.

### Claim 21 (depends on 16)

The method of claim 16, wherein the adenosine monophosphate-activated protein kinase-associated disorder is selected from cancer, type 1 diabetes, type 2 diabetes, metabolic syndrome, atherosclerosis, dyslipidemia, mitochondrial disorders, sarcopenia, obesity, hypertension, cerebral ischemia, cognitive defect Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, Friedrich's Ataxia, metabolic syndrome, atherosclerosis, dyslipidaemia, mitochondrial disorders, sarcopenia, obesity, hypertension, cerebral ischemia, organ fibrosis, amyotrophic lateral sclerosis, multiple sclerosis, tuberous sclerosis, neurofibromatosis, neuro-inflammation, inflammatory pain, neuropathic pain, epilepsy, virus infection, and aging-associated disorders.

### Claim 22 (depends on 1)

A method of inhibiting at least one of a Hippo, Wnt, and TGF beta pathway in a subject, comprising administering to the subject a compound of claim 1.

### Claim 23 (depends on 1)

A method of inhibiting an epithelial-mesenchymal transition in a cell, comprising contacting the cell with a compound of claim 1.

### Claim 24 (depends on 1)

A method of activating an adenosine monophosphate-activated protein kinase in a cell, comprising contacting the cell with a compound of claim 1.
